You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Biochemistry & Bioanalytical
DMPK
Better Pharmacokinetic Decisions Start Earlier Than You Think
One of the biggest challenges in drug discovery is not generating data. It is generating the CRITICAL data early enough to make confident development decisions.
When metabolic stability, exposure, bioavailability, or formulation issues are identified late in development, timelines lengthen, costs increase, and promising candidates may never reach the clinic. An integrated ADME/DMPK strategy helps reduce these risks by providing the pharmacokinetic insight needed to prioritize compounds, optimize lead candidates, and support successful IND-enabling studies.
At GD3, our scientists combine in vitro ADME screening, in vivo pharmacokinetic studies, and validated LC-MS/MS bioanalysis into a single integrated platform. The result is streamlined study execution, consistent scientific oversight, and high-quality data that support better decisions throughout development.
Our capabilities include:
- In vitro ADME assays, including metabolic stability, plasma protein binding, solubility, permeability, and CYP inhibition
- Multi-species in vivo DMPK and in vivo pharmacokinetic studies with flexible dosing routes and comprehensive PK analysis
- Validated bioanalysis services including LC-MS/MS bioanalytical methods for plasma, whole blood, tissue, and tumor matrices
- Integrated support from medicinal chemistry through disease modeling and toxicology
Whether you are selecting lead candidates, confirming exposure, or preparing for IND-enabling studies, GD3 provides the scientific expertise and operational flexibility to help move your program forward with confidence.